News | Investors CONTACT US Rafael Holdings LEADERSHIP RAFAEL PHARMACEUTICALS INVESTORS INVESTOR OVERVIEW Investors Investor Overview Stockholder Services Tax Documents Corporate Governance Financial Reports Annual Reports & Proxies Quarterly Earnings SEC Filings Events & Presentations Email Alerts Contact Investor Relations 12/15/2020 Rafael Holdings Reports First Quarter Fiscal Year 2021 Results Rafael Holdings and Rafael Pharmaceuticals have announced a planned merger to create an integrated pharmaceutical company developing novel cancer therapies. The merged company would adopt the Rafael Pharmaceuticals, Inc. name and would include Rafael Holdings' interests in LipoMedix Pharmaceuticals Ltd. and the Barer Institute, a wholly-owned subsidiary developing a pipeline of compounds focused on the regulation of cancer metabolism. Recent News Nov 22, 2021 Rafael Holdings Realigns Leadership Team to Support Earlier Stage Pipeline Focus Oct 28, 2021 Rafael Holdings Provides Update on Rafael Pharmaceuticals' Two Phase 3 Trials of CPI-613® (Devimistat), AVENGER 500 in Metastatic Pancreatic Cancer and ARMADA 2000 in Relapsed or Refractory Acute Myeloid Leukemia Oct 18, 2021 Rafael Holdings Announces Inducement Grant Under NYSE Rule 303A.08 Oct 18, 2021 Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2021 Financial and Operating Results and Provides Business Update Oct 6, 2021 Rafael Holdings Appoints Mimi Huizinga, MD, MPH as Chief Development and Medical Officer Real Estate Holdings Rafael Pharmaceuticals Lipomedix Pharmaceuticals Leadership Press Releases News Coverage Investors Contact Us Privacy Policy Disclaimer Copyright ©2021 Rafael Holdings, Inc. All rights reserved

News | Investors | Join our team CONTACT US Rafael Holdings LEADERSHIP RAFAEL PHARMA You are now leaving the Rafael Holdings website. You are about to leave this website for another external website. Rafael Holdings has no responsibility for the content of such other site and is not liable for any damages or injury arising from that content. This link is provided merely as a convenience to the users of this website. If you wish to access the Rafael Pharmaceuticals site, click PROCEED Leadership Rafael Pharmaceuticals Lipomedix Pharmaceuticals Press Releases News Coverage Investors Contact Us Privacy Policy Disclaimer Copyright @2018 Rafael Holdings, Inc. All rights reserved